The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Is ZTS a good stock to buy? We came across a bullish thesis on Zoetis Inc. on Quality At A Fair Price’s Substack. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.'s share was trading at $117.52 as of April 22nd. ZTS’s trailing and forward P/E were 19.52 and 16.75 respectively according to Yahoo Finance.

Lucky Business/Shutterstock.com

Zoetis Inc. (ZTS) is positioned as the global leader in animal health, specializing in medicines, vaccines, diagnostics, and technologies that support both companion and livestock animal care, and it continues to benefit from structurally durable demand trends following its spin-off from Pfizer. The Dividend Yield Theory framework suggests that despite its defensive business model and consistent earnings quality, the stock is currently mispriced, trading at $131.94 versus an implied fair value of $229, indicating a significant ~42% discount and pointing to meaningful upside potential if valuation normalizes.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The company’s dividend profile reinforces this quality narrative, with a forward yield of 1.63% compared to a 5-year average yield of just 0.93%, suggesting the current entry point is historically more attractive despite a modest recent ~6% dividend increase. Importantly, Zoetis maintains a strong track record of dividend growth, with 3-, 5-, and 10-year dividend growth rates consistently above 12%, highlighting durable cash flow generation and disciplined capital allocation.

While historical CAGR trends show periods of compression, the forward outlook shifts the narrative materially, with estimated EPS growth of 8.58% and a projected future CAGR of 17.53%, supported by valuation normalization via a 7.31% re-rating factor.

Even though recent performance has reflected volatility, the long-term structural drivers—expanding pet ownership, premiumization of animal healthcare, and recurring pharmaceutical demand—remain intact and supportive of sustained growth. Overall, Zoetis stands out as a high-quality compounder trading below intrinsic value, with dividend stability, strong growth visibility, and a compelling rerating opportunity that collectively create an attractive risk-reward setup for long-term investors.

Previously, we covered a bullish thesis on Zoetis Inc. (ZTS) by Best Anchor Stocks in December 2024, which highlighted the company’s accelerating growth driven by its OA pain MAB franchise, strong beat-beat-raise quarters, and expanding market creation. ZTS's stock price has depreciated by approximately 28.65% since our coverage. Quality At A Fair Price shares a similar view but emphasizes valuation mispricing and dividend yield-based upside potential.

Zoetis Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 69 hedge fund portfolios held ZTS at the end of the fourth quarter which was 72 in the previous quarter. While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.